Drug Approval | November 16, 2023
Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
European operations' revenue grew 58.4% to Rs 599.7 crore
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
PhytoSquene now available for clinical and commercial use
Lack of technology transfer stands out as a formidable barrier
Subscribe To Our Newsletter & Stay Updated
